Product Information
DIOVAN HCT 160-12.5 MG TAB is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $11.4646 per EA under NDC 00078031534. Its NADAC has been published 488 times since Nov 28, 2013.
FDA first approved this application on Mar 6, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the valsartan and hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
12.5; 160 mg/1; mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078031534
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; VALSARTANApproval Type
New Drug (NDA)
FDA Application
NDA020818FDA Approved
3/6/1998
TE Code
AB
On Market Since
3/6/1998
Pharmacological Classes
Price Statistics
The NADAC for DIOVAN HCT 160-12.5 MG TAB has been published 488 times since Nov 28, 2013, and over the history we have for it it has risen 170.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.4646 per EA |
|---|---|
| All-time high | $11.5353 (Jun 10, 2026) |
| All-time low | $4.2376 (Nov 28, 2013) |
| 52-week high | $11.5353 |
| 52-week low | $11.0914 |
| Median price | $8.6120 |
| Average price | $8.3345 |
| Largest weekly change | +18.1% (Jun 19, 2024) |
| Weeks tracked | 488 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of DIOVAN HCT 160-12.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for DIOVAN HCT 160-12.5 MG TAB, manufactured by Novartis Pharmaceuticals Corporation, is $11.4646 per EA (NDC 00078031534), effective Aug 19, 2026.
How has the price of DIOVAN HCT 160-12.5 MG TAB changed over time?
Over the history we have for it, the NADAC for DIOVAN HCT 160-12.5 MG TAB has risen 170.5%. It has been tracked across 488 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DIOVAN HCT 160-12.5 MG TAB?
Since Nov 28, 2013, the NADAC for DIOVAN HCT 160-12.5 MG TAB has ranged from a low of $4.2376 (Nov 28, 2013) to a high of $11.5353 (Jun 10, 2026), with a median of $8.6120 per EA.
Are there cheaper alternatives to DIOVAN HCT 160-12.5 MG TAB?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VALSARTAN-HYDROCHLOROTHIAZIDE 160-12.5 MG TAB, is $0.1027 per EA — about 99% below DIOVAN HCT 160-12.5 MG TAB.
Who manufactures DIOVAN HCT 160-12.5 MG TAB?
DIOVAN HCT 160-12.5 MG TAB (NDC 00078031534) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.